Proteon Therapeutics Inc. (NASDAQ:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it will increase the planned enrollment of its ongoing Phase 3 PATENCY-2 trial to 600 patients. The increased sample size follows a review of the statistical plan, which revealed a calculation error that overstated the trial’s power for secondary patency, one of the co-primary endpoints. The increased sample size provides 88% power to detect the differences observed in the PATENCY-1 trial with a p-value less-than or equal to0.05 for secondary patency, and 98% power with a p-value less-than or equal to0.05 for fistula use for hemodialysis, the other co-primary endpoint.
Shares of PROTEON THERAPEUTICS INC (NASDAQ:PRTO) last traded at $1.60. The company?s performance year to date is -15.79%. The 200 day simple moving average is -70.73%. The 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The price level in a market that coincides with the 200 SMA is recognized as a major support when price is above the 200 SMA or resistance when price is below the 200 SMA level.
As per recent filings, PROTEON THERAPEUTICS INC (NASDAQ:PRTO) has an insider ownership of 0.60%.
Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass.
PROTEON THERAPEUTICS INC (NASDAQ:PRTO) has been storming Wallstreet with solid press release. Recently, the company announced that according to the March 2017 study commissioned by RetailMeNot and conducted by Forrester Consulting, the company’s mobile marketing solutions generate a three-year, risk-adjusted return on investment (ROI) of 4.3x.
The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.
The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oil prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). Currently, the 5 day EMA 1.43 is lower than the last trade price suggesting a short term bullish pattern building up. Long term, the 50 day EMA 1.73 is higher than current trading price depicting a bearish pattern..
The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 55.31 suggesting a bullish price action.
PROTEON THERAPEUTICS INC (NASDAQ:PRTO) is all set to announce its earnings on May 08. As per Zack’s analyst ratings, PROTEON THERAPEUTICS INC (NASDAQ:PRTO) currently has an average brokerage rating of 2.75. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:PRTO) is $3.75 with a high of $6 and a low of $3.
As such, while we believe PROTEON THERAPEUTICS INC (NASDAQ:PRTO) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.